Evaluation for synergistic suppression of T cell responses to minor hitocompatibility antigens by chloroquine in combination with tacrolimus and a rapamycin derivative, SDZ-RAD

Bone Marrow Transplantation

Volumn 30, Issue 12, 2002, Pages 905-913

  Hsiao, C C ^a   Su, W N ^b   Forooghian, F ^b   Bader, S ^b   Rempel, J ^c   HayGlass, K T ^c   Gilman, A ^d   Schultz, K R ^b  

^a CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Bone marrow transplantation; Chloroquine; GVHD; Rapamycin; Synergy; Tacrolimus

Indexed keywords

4 AMINOQUINOLINE DERIVATIVE; CHLOROQUINE; CYCLOSPORIN A; CYTOKINE; EVEROLIMUS; HYDROXYCHLOROQUINE; MINOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; RAPAMYCIN; TACROLIMUS;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HYPOTHESIS; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LIVER TOXICITY; MOUSE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIGEN PRESENTATION; APOPTOSIS; CELLS, CULTURED; CHLOROQUINE; CYTOKINES; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MINOR HISTOCOMPATIBILITY ANTIGENS; RECOMBINANT PROTEINS; SIROLIMUS; T-LYMPHOCYTES; TACROLIMUS;

EID: 0036956143     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703727     Document Type: Article

References (29)

1. Jacoboson P, Uberti J, Davis W, Ratanatharathorn V. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Bone Marrow Transplant 1998; 22: 217-225.
2. Dumont FJ, Melino MR, Staruch MJ et al. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990; 144: 1418-1424.
3. Dumont FJ, Staruch MJ, Koprak SL et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. Immunology 1990; 144: 251-258.
4. Hess DA, Bird IA, Almawi WY, Rieder MJ. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation. J Pharmacol Exp Ther 1997; 281: 540-548.
5. Blazar BR, Taylor PA, Sehgal SN, Vallera DA. Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow. Blood 1994; 83: 600-609.
6. Fung JJ, Todo S, Tzakis A et al. Conversion of liver allograft recipients from cyclosporin to FK506-based immunosuppression: benefits and pitfalls. Transplant Proc 1991; 23: 14-21.
7. Blazar BR, Taylor PA, Sehgal SN, Vallera DA. Rapamycin prolongs survival of murine recipients of fully allogeneic donor grafts when administrated during the graft-versus-host disease process. Ann NY Acad Sci 1993; 685: 73-85.
8. Schuurman HJ, Cottens S, Fuchs S et al. SDZ RAD, a new rapamycin derivative, synergism with cyclosporin. Transplantation 1997; 64: 32-35.
9. Schuler W, Sedrani R, Cottens S et al. SDZ RAD, a new rapamycin derivative, pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36-42.
10. Schuurman HJ, Schuler W, Ringers J, Jonker M. The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation. Transplant Proc 1998; 30: 2198-2199.
11. Bohler T, Waiser J, Budde K et al. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplant Proc 1998; 30: 2195-2197.
12. Schultz KR, Bader S, Nelson D et al. Immune suppression by lysosomotropic amines and cyclosporine on T-cell responses to minor and major histocompatibility antigens. Transplantation 1997; 64: 1056-1065.
13. Schultz KR, Bader S, Paquet J, Li W. Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease. Blood 1995; 86: 4344-4352.
14. Nagai F, Ushiyama K, Kano I et al. Inhibition of calmodulin stimulation of phosphodiesterase and Ca2+, Mg2+-ATPase activities and shape change of erythrocyte ghosts by chloroquine. Biochem Pharmacol 1987; 36: 3433-3437.
15. Schultz KR, Nelson D, Bader S. Synergy between lysosomotropic amines and cyclosporin A on human T cell responses to an exogenous protein antigen, tetanus toxoid. Bone Marrow Transplant 1996; 18: 625-631.
16. Dukmans BA, Borne BE, Landewe RB et al. Chloroquine combined with cyclosporine in rheumatoid arthritis: more than the addition of 2 drugs alone. J Rheumatol 1996; 23 (Suppl. 44): 61-63.
17. Goldman FD, Gilman AL, Hollenback C et al. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 2000; 95: 3460-3466.
18. Gilman AL, Chan KW, Mogul A et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6: 327-334.
19. Yang X, Gieni RS, Mosmann TR, HayGlass KT. Chemically modified antigen preferentially elicits induction of Th1-like cytokine synthesis patterns in vivo. J Exp Med 1993; 178: 349-353.
20. Gieni RS, Li Y, HayGlass KT. Comparison of 3H-thymidine incorporation with MTT and MTS bioassays for human and murine IL-2 and IL-4 analysis: tetrazolium assays provide markedly enhanced sensitivity. J Immunol Meth 1995; 187: 85-93.
21. Lam GKY. The differential aspects of the linear isobole in the study of combined action of agents. Bull Mathe Biol 1993; 55: 295-313.
22. Berenbaum MC. Synergy, additivism, and antagonism in immunosuppression: a critical review. Clin Exp Immunol 1977; 28: 1-18.
23. Chou T-C. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 1976; 59: 253-276.
24. Kahan BD, Gibbons S, Tejpal N et al. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991; 51: 232-239.
25. Kahan BD, Chou T, Tejpal N et al. Synergistic effects of cyclosporin analogs-A, D, G, Imm-125- with rapamycin and/or brequinar. Transplant Proc 1994; 26: 3021-3024.
26. Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 1999; 162: 2772-2784.
27. Vogelsang GB. How I treat chronic GVHD. Blood 2001; 97: 1196-1201.
28. Quesniaux VFJ, Wehrli S, Steiner C et al. The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo. Blood 1994; 84: 1543-1552.
29. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Vallera DA. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. J Immunol 1998; 160: 5355-5365.